Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues
for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement
for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding
for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings;
market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the
zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications
for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all,
for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other
market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Zinc's raw materials shortfall has made it all the way down the supply chain to the refined metal
market, tightness will be here
for a while
With a
market cap of around C$ 50 million, this advanced junior could be a takeover target if the need
for reliable
zinc assets persists.
The PowerShares DB Base Metal ETF, which holds copper,
zinc and aluminum futures contracts, tells the story of a
market under pressure — it's been slowly descending
for over a year.
If I am correct on the demand - supply attributes of the silver
market, and equally correct in the historical behavior of silver relative to large speculator extremes (such as three weeks ago, when they were net short CME silver
for the first time ever), then we have an excellent chance of seeing a trading opportunity not unlike the
zinc trade of 2016 - 2017, where a senior such as Pan American Silver Corp. (PAAS: TSX; PAAS: NASDAQ) can perform like TECK did, and junior silver producers do even better.
Suffice it to say, when the global
markets need more
zinc, Teck Resources has ample resources to meet those needs, making it an excellent option
for long - term
zinc investors.
The Don Strange of Texas brand includes catering and private dining
for any location or occasion, as well as food and goods available
for purchase online through the Don Strange
Market Place, www.donstrangemarket.com, and event facilities including the Don Strange Ranch in Welfare, The Waring General Store, the Ropes Course, the Zip Line at
Zinc Hill, the Buckhorn Saloon and Museum, and the entertaining cookbook, «Don Strange of Texas: His Life and Recipes.»
We offer a great newborn range
for extra sensitive skin or eczema to the best sun care products that use 22.5 %
zinc (which is the highest concentration on the
market).
Both
zinc oxide and titanium dioxide — the two most effective physical blockers according to the EWG — are nanoparticles; it's the size of the particles that matters, and that's tough
for brands to gauge and therefore
market accurately.
The final thing that we found was that in the chemical formulation, a lot of lozenges on the
market have citric acid and many other binders; all these binders prevent
zinc from ionization and therefore render it unavailable
for action.
100 grams of lamb steak contains over 30 % of the RDA
for zinc and all the benefits of being grass - fed such as high omega 3 levels and extra vitamin A. NZ lamb is one of healthiest meats you can purchase in the
market, yet here in the UK, you can buy two NZ lamb leg steaks from Tesco only # 3.
In 2016, ZINPRO
zinc methionine was selected as a preferred supplier product
for equine and companion animal
markets.
So demand
for cheap and readily available building materials and systems will sharply increase, just as critical materials like bitumen, copper,
zinc and many others fall off the
market.
For a high - low focus, pieces came from area thrift stores to flea
markets in France, including finds such as 19th - century French
zinc butcher's shop horse head and hanging lanterns.